Hendricks Holdings has invested in NorthStar Medical Radioisotopes, which will allow the company to introduce new technologies and production methodologies for molybdenum-99 and other radioisotopes.

NorthStar’s approach will produce low specific activity molybdenum-99 without using uranium as the source material. The resulting radioisotopes will be transferred to the TechneGen generator system, according to the Madison, Wis.-based company.

NorthStar’s goal is to begin domestic production of molybdenum-99, alleviating dependency on foreign sources, added the company.